ReviewJACC. CardioOncology2021
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies:
Review in JACC. CardioOncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Cardiac Toxicity in the Treatment of Light Chain Amyloidosis: Systematic Review of Clinical Studies.Current drug safety · 2024Pooled it
- Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.JACC. Cardiovascular imaging · 2025Trial
- Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis.JACC. Cardiovascular imaging · 2024Trial
- Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.Annals of medicine · 2026Article
- Unraveling cardiac amyloidosis in Egypt: diagnostic challenges and disease outcomes.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Early Divergent Cardiac Adaptation After Hematopoietic Stem Cell Transplantation: A Multimodal Echocardiographic and Electrocardiographic Study.Diagnostics (Basel, Switzerland) · 2026Article
- Transferability of a US claims-based machine learning model for ATTRwt-CM identification: a retrospective evaluation in a German setting.Scientific reports · 2026Article
- Tailoring heart failure management in cardiac amyloidosis.Heart failure reviews · 2026Review
- Rare case of young cardiac amyloidosis: difficult diagnostic pathway in routine clinical care.European heart journal. Case reports · 2026Article
- Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging.European heart journal. Cardiovascular Imaging · 2026Review
- Article
- Cardiac Amyloidosis: Tribulations and New Frontiers.Journal of personalized medicine · 2025Review
- Cardiac Amyloidosis in the Real World: Clinical Presentations, Disease Overlap, and Therapeutic Imperatives.Reviews in cardiovascular medicine · 2025Review
- Tailored therapeutics for cardiomyopathies.Nature reviews. Cardiology · 2025Review
- Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.Annals of nuclear medicine · 2025Review
- Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis.International journal of molecular sciences · 2025Review
- Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment.Blood · 2025Article
- Investigating Local Sequence-Structural Attributes of Amyloidogenic Light Chain Variable Domains.Proteins · 2025Article
- Histopathology of Diabetic Nephropathy: Beyond Glomerular Basement Membrane Thickening.Cureus · 2025Review
- Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immunoglobulin light chain (AL) amyloidosis is an incurable plasma cell disorder characterized by deposition of fibrils of misfolded immunoglobulin free light chains (FLC) in target organs, leading to failure. Cardiac involvement is common in AL amyloidosis and represents the single most adverse prognostic feature. A high index of clinical suspicion with rapid tissue diagnosis and commencement of combinatorial, highly effective cytoreductive therapy is crucial to arrest the process of amyloid deposition and preserve organ function. The clinical use of molecularly targeted drugs, such as proteasome inhibitors and immunomodulatory agents, monoclonal antibodies such as daratumumab, and risk-adjusted autologous stem cell transplant in eligible patients, has radically changed the natural history of AL amyloidosis. Here, we review the state-of-the-art treatment landscape in AL amyloidosis with an eye toward future therapeutic venues to impact the outcome of this devastating illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.